An Introduction to Myeloproliferative Disorders
Myeloproliferative disorders include a number of conditions that are characterised by excessive accumulation of blood cells or platelets and carry a risk of progression to acute leukaemia. The discovery of mutations in the JAK2, MPL and CALR genes has increased our understanding of the pathogenesis of Philadelphia-negative myeloproliferative neoplasms (PV, MF and ET), leading to improved diagnosis and management. However, JAK2 inhibition has not produced long-term disease remission and there is a need for novel therapeutic targets. Emerging approaches include isocitrate dehydrogenase inhibitors, spliceosome inhibitors, pegylated interferon with ruxolitinib and immune checkpoint inhibitors.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape.
Myeloproliferative Disorders Content
An Exciting New Era in the Treatment of Myeloproliferative Neoplasms
Oncology & Hematology Review, 2016;12(2):71–4 DOI: https://doi.org/10.17925/OHR.2016.12.02.71
Janus kinase/signal transducer and activator of transcription inhibition A major breakthrough in understanding the molecular drivers of myeloproliferative neoplasms (MPNs) came in 2005, with the discovery of the Janus kinase 2 (JAK2) V617F driver mutation.1 Mutated JAK activates a number of downstream pathways implicated in the proliferation and survival of malignant cells, including the signal […]
Discovery of New Mutations in MPNs
Dr. Daver explains how the new genetic data on the condition is affecting prognostic factors, specifically related to high-risk mutations. He goes on to talk about continued research and the implementation of this knowledge into clinical practice.
Myeloproliferative Neoplasms Update 2015
Ruben Mesa, M.D., professor and hematologist at Mayo Clinic in Arizona, discusses the treatment and management of myeloproliferative neoplasms as well as shares highlights from the 56th Annual American Society of Hematology (ASH) meeting in San Francisco, December 2014.
When to Begin Treatment for Myeloproliferative Neoplasms
Dr. Srdan Verstovsek and Dr. Jason Gotlib discuss what doctors and patients need to consider when the time comes including financial implications, side effects, new symptoms and more.
Understanding Why Myeloproliferative Neoplasms Develop
Why do myeloproliferative neoplasms (MPNs) develop in the first place? Could I have prevented it? Mayo clinic expert Dr. Ruben Mesa provides insight on what factors may play a role in introducing MPN to the body.
Advances in Understanding and Treating MPNs
Developments could lead to more effective treatment options for people with essential thrombocythemia (ET), myelofibrosis (PMF) and polycythemia vera (PV).
Are you born with an MPN? Can MPNs be prevented
Dr. Alison Moliterno from Johns Hopkins Medicine, explains what doctors know about why MPNs occur, risks for contracting an MPN, and whether the disease may be hereditary or related to genetics.
Understanding Disease Burden Among MPNs
Dr. Ruben Mesa describes the spectrum of possible risks for patients with myeloproliferative neoplasms, particularly polycythemia vera (PV) and essential thrombocythemia (ET).
Myeloproliferative Neoplasms from the 2014 European Hematology Association
Vikas Gupta, MD discusses ABSTRACT S1358: A phase I/II, open-label study evaluating twice-daily administration of momelotinib (GS-0387, CYT387) in primary myelofibrosis or post-polycythemia vera or post-essential thrombocythemia myelofibrosis.
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!